undamentalytics Newsletter

Foukas Joshua: insider trades

Officer at Usana Health Sciences Inc. No open-market purchases and 18 sales not made under a pre-set plan, reported from September 6, 2018 to May 8, 2026.

What happened after Foukas Joshua’s sales?

After their sales, the shares moved −31.1% against the index over 12 months on average (a negative figure means selling was the right call); 94% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Foukas Joshua: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 18 −6.3% −3.8% 61% 9 −2.16 0.062 No reliable evidence
Sales, 12 months after the report 16 −31.1% −28.3% 94% 8 −5.25 0.001 Strong evidence: seller right
Sales, 12 months after the trade 16 −31.9% −25.7% 100% 8 −4.49 0.003 Strong evidence: seller right

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Usana Health Sciences Inc USNA CHIEF LEGAL OFFICER018September 6, 2018May 8, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 8, 2026May 7, 2026 USNA Sale $75,138 −25.6%not yetnot yet
February 23, 2026February 20, 2026 USNA Sale $95,242 −25.2%not yetnot yet
March 13, 2025March 12, 2025 USNA Sale $186,519 −5.0%−60.0%−66.6%
March 4, 2024February 29, 2024 USNA Sale $232,220 0.0%−44.5%−53.7%
February 17, 2023February 16, 2023 USNA Sale $230,069 −2.5%−50.4%−44.7%
August 17, 2022August 16, 2022 USNA Sale $17,866 −22.3%−18.3%−15.1%
March 4, 2022March 2, 2022 USNA Sale $297,039 −10.5%−26.1%−22.8%
October 29, 2021October 28, 2021 USNA Sale $17,226 −1.8%−30.4%−27.8%
August 9, 2021August 5, 2021 USNA Sale $24,170 +0.4%−23.5%−22.8%
February 16, 2021February 11, 2021 USNA Sale $276,128 +4.1%−19.2%−23.5%
October 27, 2020October 26, 2020 USNA Sale $16,560 −11.0%−24.7%−18.6%
August 21, 2020August 20, 2020 USNA Sale $22,450 −8.2%−11.9%−18.2%
April 27, 2020April 23, 2020 USNA Sale $162,175 −16.5%−42.4%−32.3%
February 10, 2020February 6, 2020 USNA Sale $123,793 +17.4%+4.9%−13.9%
October 30, 2019October 28, 2019 USNA Sale $83,101 −22.3%−7.7%−0.7%
October 31, 2018October 29, 2018 USNA Sale $32,400 +3.7%−46.4%−49.3%
September 14, 2018September 12, 2018 USNA Sale $39,557 +5.8%−49.8%−51.0%
September 6, 2018September 4, 2018 USNA Sale $821,568 +5.2%−46.8%−49.6%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Foukas Joshua traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.